A citation-based method for searching scientific literature

Kristen M Smith, Patrick C Fagan, Elena Pomari, Giuseppe Germano, Chiara Frasson, Colin Walsh, Ian Silverman, Paolo Bonvini, Gang Li. Mol Cancer Ther 2018
Times Cited: 21







List of co-cited articles
148 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
47

TRKing down an old oncogene in a new era of targeted therapy.
Aria Vaishnavi, Anh T Le, Robert C Doebele. Cancer Discov 2015
302
38

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung Ju Ahn, Jeeyun Lee, Todd M Bauer, Anna F Farago, Jennifer J Wheler, Stephen V Liu,[...]. Cancer Discov 2017
403
38

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Elena Ardini, Maria Menichincheri, Patrizia Banfi, Roberta Bosotti, Cristina De Ponti, Romana Pulci, Dario Ballinari, Marina Ciomei, Gemma Texido, Anna Degrassi,[...]. Mol Cancer Ther 2016
152
33

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
A Drilon, G Li, S Dogan, M Gounder, R Shen, M Arcila, L Wang, D M Hyman, J Hechtman, G Wei,[...]. Ann Oncol 2016
170
33

NTRK fusion-positive cancers and TRK inhibitor therapy.
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon. Nat Rev Clin Oncol 2018
426
33

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
A Vaishnavi, M Capelletti, A T Le, S Kako, M Butaney, D Ercan, S Mahale, K D Davies, D L Aisner, A B Pilling,[...]. Nat Med 2013
369
28

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Mariangela Russo, Sandra Misale, Ge Wei, Giulia Siravegna, Giovanni Crisafulli, Luca Lazzari, Giorgio Corti, Giuseppe Rospo, Luca Novara, Benedetta Mussolin,[...]. Cancer Discov 2016
171
28

A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.
S R Knezevich, D E McFadden, W Tao, J F Lim, P H Sorensen. Nat Genet 1998
527
23

Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.
Cristina Tognon, Stevan R Knezevich, David Huntsman, Calvin D Roskelley, Natalya Melnyk, Joan A Mathers, Laurence Becker, Fatima Carneiro, Nicol MacPherson, Doug Horsman,[...]. Cancer Cell 2002
552
23

Targeting TRK family proteins in cancer.
Yekaterina B Khotskaya, Vijaykumar R Holla, Anna F Farago, Kenna R Mills Shaw, Funda Meric-Bernstam, David S Hong. Pharmacol Ther 2017
126
23

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
Bruce W Konicek, Andrew R Capen, Kelly M Credille, Philip J Ebert, Beverly L Falcon, Gary L Heady, Bharvin K R Patel, Victoria L Peek, Jennifer R Stephens, Julie A Stewart,[...]. Oncotarget 2018
28
23

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.
Alessio Amatu, Andrea Sartore-Bianchi, Salvatore Siena. ESMO Open 2016
251
23

Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25).
M Eguchi, M Eguchi-Ishimae, A Tojo, K Morishita, K Suzuki, Y Sato, S Kudoh, K Tanaka, M Setoyama, F Nagamura,[...]. Blood 1999
206
19

TrkA overexpression enhances growth and metastasis of breast cancer cells.
C Lagadec, S Meignan, E Adriaenssens, B Foveau, E Vanhecke, R Romon, R-A Toillon, B Oxombre, H Hondermarck, X Le Bourhis. Oncogene 2009
133
19

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, Roberto Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo,[...]. J Med Chem 2016
115
19

Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Christian Rolfo, Rossana Ruiz, Elisa Giovannetti, Ignacio Gil-Bazo, Antonio Russo, Francesco Passiglia, Marco Giallombardo, Marc Peeters, Luis Raez. Expert Opin Investig Drugs 2015
67
19

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Robert C Doebele, Lara E Davis, Aria Vaishnavi, Anh T Le, Adriana Estrada-Bernal, Stephen Keysar, Antonio Jimeno, Marileila Varella-Garcia, Dara L Aisner, Yali Li,[...]. Cancer Discov 2015
222
19

Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia.
G W Reuther, Q T Lambert, M A Caligiuri, C J Der. Mol Cell Biol 2000
80
19

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Alexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, Nora Ku, Brian B Tuch, Kevin Ebata, Steve Smith, Veronique Lauriault, Gabrielle R Kolakowski, Barbara J Brandhuber,[...]. Cancer Discov 2017
190
19

Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
Miho J Fuse, Koutaroh Okada, Tomoko Oh-Hara, Hayato Ogura, Naoya Fujita, Ryohei Katayama. Mol Cancer Ther 2017
46
19

Trk receptors: roles in neuronal signal transduction.
Eric J Huang, Louis F Reichardt. Annu Rev Biochem 2003
19

Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.
Michael H Tomasson, Zhifu Xiang, Richard Walgren, Yu Zhao, Yumi Kasai, Tracie Miner, Rhonda E Ries, Olga Lubman, Daved H Fremont, Michael D McLellan,[...]. Blood 2008
155
19

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
Justin Taylor, Dean Pavlick, Akihide Yoshimi, Christina Marcelus, Stephen S Chung, Jaclyn F Hechtman, Ryma Benayed, Emiliano Cocco, Benjamin H Durham, Lillian Bitner,[...]. J Clin Invest 2018
29
19

Molecular characterization of cancers with NTRK gene fusions.
Zoran Gatalica, Joanne Xiu, Jeffrey Swensen, Semir Vranic. Mod Pathol 2019
185
19


Rearrangements of NTRK1 gene in papillary thyroid carcinoma.
A Greco, C Miranda, M A Pierotti. Mol Cell Endocrinol 2010
118
14

Inhibiting TRK Proteins in Clinical Cancer Therapy.
Allison M Lange, Hui-Wen Lo. Cancers (Basel) 2018
76
14

Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Ramamoorthy Nagasubramanian, Julie Wei, Paul Gordon, Jeff C Rastatter, Michael C Cox, Alberto Pappo. Pediatr Blood Cancer 2016
75
14

Infantile NTRK-associated Mesenchymal Tumors.
Jessica L Davis, Christina M Lockwood, Catherine M Albert, Karen Tsuchiya, Douglas S Hawkins, Erin R Rudzinski. Pediatr Dev Pathol 2018
59
14

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Anna F Farago, Long P Le, Zongli Zheng, Alona Muzikansky, Alexander Drilon, Manish Patel, Todd M Bauer, Stephen V Liu, Sai-Hong I Ou, David Jackman,[...]. J Thorac Oncol 2015
146
14


Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Jaclyn F Hechtman, Ryma Benayed, David M Hyman, Alexander Drilon, Ahmet Zehir, Denise Frosina, Maria E Arcila, Snjezana Dogan, David S Klimstra, Marc Ladanyi,[...]. Am J Surg Pathol 2017
199
14

Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.
Peter J Cook, Rozario Thomas, Ram Kannan, Esther Sanchez de Leon, Alexander Drilon, Marc K Rosenblum, Maurizio Scaltriti, Robert Benezra, Andrea Ventura. Nat Commun 2017
37
14

ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition.
Kathryn G Roberts, Laura J Janke, Yaqi Zhao, Aman Seth, Jing Ma, David Finkelstein, Steve Smith, Kevin Ebata, Brian B Tuch, Stephen P Hunger,[...]. Blood 2018
22
14


The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.
Gang Wu, Alexander K Diaz, Barbara S Paugh, Sherri L Rankin, Bensheng Ju, Yongjin Li, Xiaoyan Zhu, Chunxu Qu, Xiang Chen, Junyuan Zhang,[...]. Nat Genet 2014
579
14

High-affinity neurotrophin receptors and ligands promote leukemogenesis.
Zhixiong Li, Gernot Beutel, Mathias Rhein, Johann Meyer, Christian Koenecke, Thomas Neumann, Min Yang, Jürgen Krauter, Nils von Neuhoff, Michael Heuser,[...]. Blood 2009
40
14

Neurotrophins and the immune system.
José A Vega, Olivia García-Suárez, Jonas Hannestad, Marta Pérez-Pérez, Antonino Germanà. J Anat 2003
170
14

Expression of neurotrophins and their receptors in human bone marrow.
E Labouyrie, P Dubus, A Groppi, F X Mahon, J Ferrer, M Parrens, J Reiffers, A de Mascarel, J P Merlio. Am J Pathol 1999
141
14

Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells.
Mikko Taipale, Irina Krykbaeva, Luke Whitesell, Sandro Santagata, Jianming Zhang, Qingsong Liu, Nathanael S Gray, Susan Lindquist. Nat Biotechnol 2013
76
14


Detecting and targetting oncogenic fusion proteins in the genomic era.
Monika A Davare, Cristina E Tognon. Biol Cell 2015
22
14

Expression of the nerve growth factor receptor c-TRK in human myeloid leukaemia cells.
A Kaebisch, S Brokt, U Seay, J Lohmeyer, U Jaeger, H Pralle. Br J Haematol 1996
18
16

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
161
14

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Kathryn G Roberts, Yongjin Li, Debbie Payne-Turner, Richard C Harvey, Yung-Li Yang, Deqing Pei, Kelly McCastlain, Li Ding, Charles Lu, Guangchun Song,[...]. N Engl J Med 2014
763
14

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
Tamilla Nechiporuk, Stephen E Kurtz, Olga Nikolova, Tingting Liu, Courtney L Jones, Angelo D'Alessandro, Rachel Culp-Hill, Amanda d'Almeida, Sunil K Joshi, Mara Rosenberg,[...]. Cancer Discov 2019
80
14

ETV6-NTRK3 as a therapeutic target of small molecule inhibitor PKC412.
Hoang Thanh Chi, Bui Thi Kim Ly, Yasuhiko Kano, Arinobu Tojo, Toshiki Watanabe, Yuko Sato. Biochem Biophys Res Commun 2012
36
9

ETV6 fusion genes in hematological malignancies: a review.
Etienne De Braekeleer, Nathalie Douet-Guilbert, Frédéric Morel, Marie-Josée Le Bris, Audrey Basinko, Marc De Braekeleer. Leuk Res 2012
105
9



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.